期刊
STEM CELLS
卷 26, 期 11, 页码 2753-2758出版社
WILEY
DOI: 10.1634/stemcells.2008-0421
关键词
Induced pluripotent stem cells; Embryonic stem cell; Somatic cell nuclear transfer; Pluripotency; Reprogramming
资金
- Craig H. Neilsen Foundation
- NIH [R01-NS048382]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048382] Funding Source: NIH RePORTER
The development of personalized pluripotent stem cells for research and for possible therapies holds out great hope for patients. However, such cells will face significant technical and regulatory challenges before they can be used as therapeutic reagents. Here we consider two possible sources of personalized pluripotent stem cells: embryonic stem cells derived from nuclear transfer (NT-ESCs) and induced pluripotent stem cells (iPSCs) derived from direct reprogramming of adult somatic cells. Both sources of personalized pluripotent stem cells face unique regulatory hurdles that are in some ways significantly higher than those facing stem cells derived from embryos produced by fertilization (ESCs). However, the outstanding long-term potential of iPSCs and their relative freedom from the ethical concerns raised by both ESCs and NT-ESCs makes direct reprogramming an exceptionally promising approach to advancing research and providing therapies in the field of regenerative medicine. STEM CELLS 2008;26:2753-2758
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据